Cytek Biosciences Inc (CTKB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cytek Biosciences Inc (CTKB) has a cash flow conversion efficiency ratio of -0.008x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.74 Million) by net assets ($327.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CTKB market cap overview for the company's overall valuation and market capitalisation.
Cytek Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Cytek Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cytek Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytek Biosciences Inc ranked by their cash flow conversion efficiency. Explore Cytek Biosciences Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Meida Industrial Co Ltd
SHE:002677
|
0.005x |
|
Bintulu Port Holdings Bhd
KLSE:5032
|
-0.010x |
|
Nanjing University Environmental
SHE:300864
|
0.007x |
|
CJ CGV
KO:079160
|
0.005x |
|
Optiemus Infracom Limited
NSE:OPTIEMUS
|
-0.061x |
|
Jinling Pharmaceutical Co Ltd
SHE:000919
|
0.015x |
|
Sharda Motor Industries Limited
NSE:SHARDAMOTR
|
0.127x |
|
Tungkong Inc
SHE:002117
|
0.055x |
Annual Cash Flow Conversion Efficiency for Cytek Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Cytek Biosciences Inc from 2019 to 2025. View current stock price of Cytek Biosciences Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $341.74 Million | $-4.69 Million | -0.014x | -121.38% |
| 2024-12-31 | $395.74 Million | $25.38 Million | 0.064x | +377.33% |
| 2023-12-31 | $393.06 Million | $5.28 Million | 0.013x | +146.75% |
| 2022-12-31 | $425.55 Million | $-12.23 Million | -0.029x | -351.65% |
| 2021-12-31 | $405.38 Million | $4.63 Million | 0.011x | +101.21% |
| 2020-12-31 | $-16.03 Million | $15.16 Million | -0.946x | -386.84% |
| 2019-12-31 | $-41.70 Million | $-13.75 Million | 0.330x | -- |
About Cytek Biosciences Inc
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies usin… Read more